Inventor · disambiguated record
Ping Zhu
Also filed as: ZHU PING · ZHU PING AN
25 granted patents·18 pending applications·57 citations·filing 1999–2025
94Inventor score
Files withEISAI R&D MAN CO LTD17ARROWHEAD PHARMACEUTICALS INC3SHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD3ARROWHEAD RES CORP2BIOCONTROL SYSTEMS INC2
Top patents by PatentIndex Score
43 records- 0186US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 0286US2025135017A1Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2024·Application pending·0 cites
- 0385US9796683B2Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2016·Granted Oct 24, 2017·6 cites·32 claims
- 0485US9540643B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2015·Granted Jan 10, 2017·3 cites·21 claims
- 0585US8481509B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2012·Granted Jul 9, 2013·6 cites·20 claims
- 0684US12043670B2Anti-BCMA antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2021·Granted Jul 23, 2024·1 cites·48 claims
- 0784US11352348B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2020·Granted Jun 7, 2022·1 cites·25 claims
- 0884US8293718B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2010·Granted Oct 23, 2012·5 cites·51 claims
- 0983US12091661B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 1083US9096637B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2013·Granted Aug 4, 2015·3 cites·22 claims
- 1182US10889866B2Splice variants associated with neomorphic SF3B1 mutantsEISAI R&D MAN CO LTD·Filed 2016·Granted Jan 12, 2021·2 cites·18 claims
- 1282US8623838B2Organic compositions to treat HSF1-related diseasesCHEN JINYUN·Filed 2012·Granted Jan 7, 2014·6 cites·22 claims
- 1377US11945807B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2022·Granted Apr 2, 2024·0 cites·24 claims
- 1477US11091761B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Aug 17, 2021·0 cites·20 claims
- 1573US8338573B2Crystal structure of CD147 extracellular region and use thereofCHEN ZHINAN·Filed 2007·Granted Dec 25, 2012·2 cites·4 claims
- 1672US2024327535A1Anti-bcma antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2024·Application pending·0 cites
- 1770US12172986B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2019·Granted Dec 24, 2024·0 cites·46 claims
- 1870US8435962B2Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fatZHU HAIBO·Filed 2009·Granted May 7, 2013·3 cites·10 claims
- 1970US2024350484A1Methods of using splicing modulatorsEISAI R&D MAN CO LTD·Filed 2024·Application pending·0 cites
- 2064US11998544B2Methods of using splicing modulatorsEISAI R&D MAN CO LTD·Filed 2019·Granted Jun 4, 2024·0 cites·12 claims
- 2163US11761045B2Splice variants associated with neomorphic SF3B1 mutantsEISAI R&D MAN CO LTD·Filed 2020·Granted Sep 19, 2023·0 cites·25 claims
- 2258US6955532B2Method and apparatus for the manufacture of high temperature materials by combustion synthesis and semi-solid formingUNIV ROCHESTER·Filed 2002·Granted Oct 18, 2005·5 cites·17 claims
- 2353US2008269106A1Methods and Compositions for Diagnosis and Treatment of Disorders Involving MacrophagesROSENFELD MICHAEL·Filed 2006·Application pending·0 cites
- 2451US2002127699A1Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopesBIOCONTROL SYSTEMS INC·Filed 2002·Application pending·0 cites
- 2550US2025243273A1Humanized anti-basigin antibodies and the use thereofFOURTH MILITARY MEDICAL UNIV·Filed 2025·Application pending·0 cites
- 2650US2018141913A1Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 2750US2020255415A1Tetrasubstituted alkene compounds and their use for the treatment of breast cancerEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 2849US10851065B2Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Granted Dec 1, 2020·0 cites·20 claims
- 2948US2013231472A1Use of molecular markers for the preclinical profiling of inhibitors of enzymes having histone deacetylase activityHEINZEL THORSTEN·Filed 2012·Application pending·0 cites
- 3047US10011874B2Androgen receptor mutationNOVARTIS AG·Filed 2014·Granted Jul 3, 2018·0 cites·2 claims
- 3144US12240901B2Humanized anti-BASIGIN antibodies and the use thereofFOURTH MILITARY MEDICAL UNIV·Filed 2017·Granted Mar 4, 2025·0 cites·12 claims
- 3244US6379918B1Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopesBIOCONTROL SYSTEMS INC·Filed 1999·Granted Apr 30, 2002·11 cites·25 claims
- 3343US2020190593A1Spliceosome mutations and uses thereofEISAI R&D MAN CO LTD·Filed 2018·Application pending·0 cites
- 3442US2006110735A1Use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activityHEINZEL THORSTEN·Filed 2003·Application pending·0 cites
- 3539US11524009B2Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of useEISAI R&D MAN CO LTD·Filed 2018·Granted Dec 13, 2022·0 cites·34 claims
- 3638US2019255564A1Omniphobic porous membrane and methods for preparing the sameUNIV HONG KONG·Filed 2016·Application pending·0 cites
- 3738US2019337921A1Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 3837US2020299573A1Composite comprising semiconductor nanocrystals and method of preparing the sameDOW GLOBAL TECHNOLOGIES LLC·Filed 2016·Application pending·0 cites
- 3934US2018017496A1Method for detecting dissolution rate of preparation containing colloidal bismuth pectinSHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 4033US2005026841A1Hab18g/cd147 its antagonist and applicationFiled 2002·Application pending·0 cites
- 4131US2017095507A1Dispersion preparation containing colloidal bismuth pectin and preparing method thereforSHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD·Filed 2015·Application pending·0 cites
- 4231US2018017497A1Method for measuring bismuth content in colloidal bismuth pectin or colloidal bismuth pectin-contained preparationSHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 4328US9206405B2Glycosyl hydrolase with beta-xylosidase and beta-glucosidase activities and uses thereofZHU PING·Filed 2011·Granted Dec 8, 2015·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Ping Zhu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →